Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection

Vaccine. 2022 Sep 16;40(39):5726-5731. doi: 10.1016/j.vaccine.2022.08.045. Epub 2022 Aug 26.

Abstract

In the present study, immunogenicity data in 61 vaccinated healthcare workers (HCWs) either infection naïve (naïve HCWs) or with infection of Delta and/or Omicron COVID-19 (experienced HCWs) were evaluated up to 270 days after the second dose of BNT162b2 vaccine and up to 90 days after a booster dose. A decrease in antibody levels at 270 days following administration of the second dose (p = 0.0335) was observed, although values did not fall below the positivity threshold (33.8 BAU/ml). After booster vaccination, antibody levels increased after 30 days (p = 0.0486), with much higher values than after first and second vaccination. Antibody levels then decreased at 60 and 90 days after the booster dose. A comparison between mean antibody levels of naïve and experienced HCWs revealed higher values in experienced HCWs, resulting from both natural and vaccination-induced immunity. A total of 14.7% of HCWs contracted the Omicron virus variant after the vaccine booster, although none showed severe symptoms. These results support that a booster dose results in a marked increase in antibody response that subsequently decreases over time.

Keywords: Booster vaccination; Humoral immune response; Immunisation safety; Neutralizing antibodies; Omicron variant; SARS-CoV-2.

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine
  • COVID-19* / prevention & control
  • Health Personnel
  • Hepatitis B Vaccines
  • Humans
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • Hepatitis B Vaccines
  • BNT162 Vaccine